Luminopia, Inc. is pioneering a new class of treatments for significant neuro-visual disorders. Luminopia is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children's Hospital*, the company is developing its lead product to improve vision in children with amblyopia, the leading cause of vision loss among children.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/11/22 | $5,700,000 | Seed Extension |
ShangBay Capital Sony Innovation Fund SSI Strategy The Vertical Group | undisclosed |
| 06/28/23 | $16,000,000 | Series A |
Broadfin Capital ShangBay Capital US Venture Partners Vertical Group | undisclosed |
